Alnylam Pharmaceuticals (ALNY) Stock Price, Quote & News

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 551 8200

Fax: 617 551 8101

Website: www.alnylam.com

Address:

675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States

zztopps Sep. 8 at 11:40 AM

$ALNY Down largely because it wasn't included in S& P quarterly rebalance?

0 · Reply

OnlyFibs Sep. 7 at 8:57 PM

$ALNY | Alnylam Pharmaceuticals, Inc. (Healthcare / RNAi Therapeutics 🧬🔬⚡️) $ALNY is commercializing RNA interference (RNAi) drugs (Amvuttra, Onpattro) to "silence" disease-causing genes before bad proteins form. The company is profitable with surging quarter-over-quarter revenue driven by Amvuttra's rapid market adoption. Technically, $ALNY is rebounding off its $205.48 double-bottom support, currently consolidating right under $269.94–$272.00 resistance. A firm break above $272.00 triggers a squeeze toward the 200-day moving average at $291.10 and macro resistance at $339.41. Key Technical Levels: • Confirmation Trigger: $272.00 🚀 • Pivot Support: $240.00 🐂 • Overhead Target 1: $291.10 🎯 • Overhead Target 2: $339.41 💰 • Downside Risk Level: $205.48 🐻 • Stop Loss: $235.00 🔴 Flow & Market Bias: Structure: 1W Trendline Reversal / Base Support Recovery Bias: Bullish above $240.00 #ALNY #stockmarket #technicalanalysis #swingtrading #hovdid

0 · Reply

OnlyFibs Sep. 7 at 8:55 PM

$ALNY up 20% and we are just getting started look at the BUY volume.

0 · Reply

stu4 Sep. 5 at 2:30 PM

$ALNY Gee South Carolina , must have had ICE take out all the MAGA morons !!!

0 · Reply

johnnygogogo Sep. 2 at 9:29 PM

$ALNY or maybe not… pretty clear either way that media is owned / controlled by institutions

0 · Reply

BiotechButterflies Sep. 2 at 4:54 PM

$ALNY ..we,ve seen the bottom... not getting in this cheap again....

0 · Reply

droptopfibonacci Sep. 2 at 4:40 PM

$ALNY we have a runner!

0 · Reply

lapulce02 Sep. 1 at 7:28 PM

$ALNY 👀

0 · Reply

DonCorleone77 Aug. 31 at 9:57 AM

$ALNY Alnylam announces new data at ESC Congress on AMVUTTRA Alnylam Pharmaceuticals announced new data at the European Society of Cardiology, ESC, Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA across transthyretin amyloidosis, ATTR, patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world's leading cause of cardiovascular disease. "With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care," said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. "The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With zilebesiran, we have the potential to extend the precision and durability of RNAi to uncontrolled hypertension. Together, these programs reflect our ambition to change the course of cardiovascular disease for patients with high unmet need."

0 · Reply

stu4 Aug. 30 at 6:05 PM

$ALNY The work of John, when CEO, and associates makes nah sayers , run with their tales between their legs , in other words , fcuk off ! Move over AstraZeneca …there is a new guy in town , and his name IS NOT , TAK . @drizz @telomerase , nor bugle boy , @RaphaelRapoport

1 · Reply

Alnylam Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference

2026-09-08T10:45:21.000Z - 5 days ago

Alnylam price target raised to $260 from $230 at Jefferies

Sep 2, 2026, 8:00 AM EDT - 11 days ago

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

2026-08-30T20:20:06.000Z - 14 days ago

Alnylam announces new data at ESC Congress on AMVUTTRA

Aug 30, 2026, 8:23 AM EDT - 14 days ago

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

Aug 30, 2026, 7:00 AM EDT - 14 days ago

Alnylam Pharmaceuticals Slides: ESC Congress Presentation

2026-08-24T12:40:25.000Z - 20 days ago

Alnylam to present new clinical data on ATTR, hypertension at ESC Congress

Aug 24, 2026, 8:33 AM EDT - 20 days ago

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

2026-08-18T20:35:52.000Z - 26 days ago

BMO Capital starts Alnylam at Outperform, sees attractive valuation

2026-08-18T20:20:16.000Z - 26 days ago

Alnylam initiated with an Outperform at BMO Capital

2026-08-17T09:17:35.000Z - 27 days ago

Alnylam award from Veterans Affairs posted to SAM.gov site

2026-08-16T13:49:05.000Z - 4 weeks ago

Alnylam price target lowered to $256 from $316 at Wells Fargo

2026-08-05T14:24:09.000Z - 5 weeks ago

Alnylam price target lowered to $325 from $400 at Evercore ISI

Aug 5, 2026, 4:28 AM EDT - 5 weeks ago

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

2026-08-04T14:25:30.000Z - 5 weeks ago

Alnylam price target lowered to $455 from $485 at H.C. Wainwright

2026-08-04T11:25:27.000Z - 5 weeks ago

Alnylam price target lowered to $315 from $410 at Truist

2026-08-03T11:26:02.000Z - 5 weeks ago

Alnylam upgraded to Strong Buy from Outperform at Raymond James

2026-08-03T10:31:12.000Z - 5 weeks ago

Alnylam price target lowered to $340 from $380 at Citi

2026-08-03T09:20:32.000Z - 5 weeks ago

Alnylam price target lowered to $450 from $527 at Barclays

2026-07-31T12:46:57.000Z - 6 weeks ago

Alnylam price target lowered to $346 from $410 at BofA

Jul 30, 2026, 8:30 AM EDT - 6 weeks ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 6 weeks ago

Alnylam Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 6 weeks ago

Alnylam Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 6 weeks ago

Alnylam Pharmaceuticals Slides: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 6 weeks ago

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

Jul 16, 2026, 8:00 AM EDT - 1 month ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Jul 15, 2026, 3:30 AM EDT - 2 months ago

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Jul 9, 2026, 7:38 AM EDT - 2 months ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AZN IONS

Jun 25, 2026, 11:00 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Study update

Jun 25, 2026, 11:00 AM EDT - 2 months ago

Alnylam Pharmaceuticals Slides: Study update

Jun 25, 2026, 9:00 AM EDT - 2 months ago

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Jun 17, 2026, 12:30 PM EDT - 2 months ago

The Healthcare M&A Wave

ABT AMGN AMRX ANTX AZN BDX BEAM

Jun 12, 2026, 9:00 AM EDT - 3 months ago

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Jun 10, 2026, 7:47 AM EDT - 3 months ago

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Jun 9, 2026, 11:20 AM EDT - 3 months ago

Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 5:06 PM EDT - 3 months ago

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

ALAB BE RDDT

Jun 3, 2026, 6:05 PM EDT - 3 months ago

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Jun 3, 2026, 4:45 PM EDT - 3 months ago

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

May 20, 2026, 10:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Transcript: AGM 2026

May 19, 2026, 8:30 AM EDT - 3 months ago

Alnylam Issues 2025 Corporate Responsibility Report

May 13, 2026, 1:40 PM EDT - 4 months ago

Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:30 AM EDT - 4 months ago

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 7, 2026, 8:00 AM EDT - 4 months ago

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 4, 2026, 8:30 AM EDT - 4 months ago

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Apr 6, 2026, 2:14 PM EDT - 5 months ago

An S&P 500 change may be imminent. These stocks are leading contenders to join the index.

IVV SPXL SPY SSO UPRO VOO FERG

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Mar 30, 2026, 1:00 PM EDT - 5 months ago

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Press release: Status update

Mar 24, 2026, 9:30 AM EDT - 5 months ago

Alnylam Pharmaceuticals Slides: Status update

Mar 24, 2026, 9:00 AM EDT - 5 months ago

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

Mar 24, 2026, 7:30 AM EDT - 5 months ago

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Mar 11, 2026, 11:55 AM EDT - 6 months ago

How Alnylam Stock Weathers Market Shocks

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Alnylam to Webcast TTR Investor Webinar

Mar 5, 2026, 9:10 AM EST - 6 months ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

TNYA

Mar 5, 2026, 8:30 AM EST - 6 months ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

TNYA

Mar 2, 2026, 9:10 AM EST - 6 months ago